Login to Your Account



AV Therapeutics tackles next-gen prostate cancer therapy

By Catherine Shaffer
Staff Writer

Thursday, January 9, 2014
AV Therapeutics Inc. decloaked in late December by merging with a public shell company. It is developing a chemotherapy candidate, capridine, that has been shown in preclinical models to have activity against prostate and colon cancer, with plans to launch Phase I trials in the second quarter of 2014.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription